Published on in Vol 11, No 10 (2022): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/37452, first published .
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial

The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial

The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial

Journals

  1. Deinichenko O, Sіusіuka V, Krut’ Y, Pavlyuchenko M, Puchkov V, Shevchenko A, Kolokot N. Clinical and pathogenetic mechanisms of formation of fetal growth retardation. Reproductive health of woman 2023;(3):24 View
  2. Palmrich P, Kalafat E, Pateisky P, Schirwani‐Hartl N, Haberl C, Herrmann C, Khalil A, Binder J. Prognostic value of angiogenic markers in pregnancy with fetal growth restriction. Ultrasound in Obstetrics & Gynecology 2024;63(5):619 View
  3. Ramirez Zegarra R, Ghi T, Lees C. Does the use of angiogenic biomarkers for the management of preeclampsia and fetal growth restriction improve outcomes?: Challenging the current status quo. European Journal of Obstetrics & Gynecology and Reproductive Biology 2024;300:268 View